Faecal Calprotectin Test– Your Choice
The widest range of calprotectin stool test formats for assessment within primary care, Gastroenterology clinics or the hospital laboratory.
What is Faecal Calprotectin?
Faecal calprotectin is a reliable, proven protein biomarker that enables non-invasive differentiation between patients with Irritable Bowel Syndrome (IBS) and those with Inflammatory Bowel Disease (IBD). The simple diagnostic test is helping to improve patient care and reduce health care costs by screening out IBS patients and preventing the need for unnecessary endoscopy procedures.
It is also proving helpful in monitoring known IBD patients to predict potential relapse and adjust medication accordingly.
Alpha Laboratories is the exclusive UK partner for BÜHLMANN Calprotectin, supporting the full range of calprotectin assay kit formats, and has many years expertise in this area.
Future proof your Calprotectin testing with BÜHLMANN Assays for all your testing requirements
- IBDoc® patient self-testing for IBD monitoring
- Quantum Blue - Point of care testing
- fCAL™ ELISA - High throughput laboratory testing covering the range 10-1800μg/g
- fCAL™ turbo - High throughput turbidimetric assay for clinical chemistry platforms
- Standardised assays for consistent results
- Simplified sample preparation using CALEX extraction devices
Find out more at our dedicated Calprotectin Website:
Measurement of faecal calprotectin is considered a reliable indicator of inflammation and numerous studies show that while faecal calprotectin concentrations are significantly elevated in patients with IBD, patients suffering from IBS do not have increased calprotectin levels.
Such increased levels in a calprotectin test are shown to correlate well with both endoscopic and histological assessment of disease activity.
In 2013 NICE published it’s Diagnostics Guidance DG11 that recommended that the faecal calprotectin test be used to help doctors distinguish between IBDs, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as IBS.
Differential diagnosis: Excellent negative predictive value enabling non-invasive differentiation between organic IBD and functional IBS.
Therapy monitoring: Ensure compliance and successful therapy by detecting a decrease in calprotectin levels.
Relapse prediction: An increase in calprotectin can be an indicator for possible IBD relapse in the future
Alpha Laboratories has a range of calprotectin test formats to best suit your needs.
- Quantum Blue® Rapid Assays for Point of Care and low throughput use
- fCal ELISA for higher throughput laboratory use with automation available on the Dynex DS2™ ELISA Processing System.
- IBD patient home monitoring with the IBDoc system
The symptoms of organic inflammatory bowel disease (IBD) and those of functional disorders such as Irritable Bowel Syndrome (IBS) can be very similar in presentation.
Historically, clinical gastroenterologists have had to use invasive endoscopy to differentially diagnose between these conditions. Not only is this stressful for the patient it carries a certain risk and is costly and time consuming for the NHS.
Using faecal calprotectin testing screens out IBS patients with an in vitro test, preventing the need for unnecessary endoscopy procedures.
Download the selection of Clinical Publications Summaries Document
Buhlmann Calprotectin Assays Literature References
1. Faecal Calprotectin: comparative study of the Quantum Blue® rapid test and an established ELISA method. Liselotte Coorevits, Filip J. Baert and Hilde J.M. Vanpouke
Clin. Chem. Lab. Med. 2012; 51:4
2. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. Manz et al.
BMC Gastroenterology 2012; 12:5
3. Faecal Calprotectin: Validation of a Laboratory Marker for Intestinal Inflammation. L. Claerys, L.Moortgat, F. Baert, H. Vanpoucke.
University of Gent Poster
4. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. Michael J. Sydora, Beate C. Sydora, Richard N. Fedorak. Journal of Crohn's and Colitis (2012) 6, 207-214
5. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis.Triana Lobatón Ortega, Francisco Rodríguez-Moranta, Jordi Guardiola Capón, Elena Sánchez Pastor, Lorena Rodríguez Alonso, Alexandra Ruiz Cerulla, Alicia López García. Department of Gastroenterology. Bellvitge University Hospital. Barcelona. Spain. DOI: 10.1097/MIB.0b013e3182802b6e
6. Calprotectin in biomarker-mediated drug development: Method validation for the quantification of fecal Calprotectin. Ronald Vermunt, Marcel van der Linden and Edwin Janssen. POSTER: Eurofins Medinet B.V., Department of Biomarkers & Biopharmaceuticals, Breda, The Netherlands
7. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. Jan Hessels, Geke Douw, Duygu D. Yildirim, Gerrit Meerman, Margot A. van Herwaarden and Frank A.J.T.M. van den Bergh. Clin Chem Lab Med. 2012 Jan 13;50(6):1079-82.
8. Monoclonal antibody testing for faecal calprotectin is superior to polyclonal testing of faecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Emanuel Burri, Michael Manz, Claude Rothen, Livio Rossi , Christoph Beglinger, Frank Serge Lehmann. Clinica chimica acta; international journal of clinical chemistry (Impact Factor: 2.76). 11/2012; 416.
9. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study
James Turvill, Assad Aghahoseini, Nala Sivarajasingham, Kazim Abbas, Murtaza Choudhry, Kostantinos Polyzois, Kostantinos Lasithiotakis, Dimitra Volanaki, Baek Kim, Fiona Langlands, Helen Andrew, Jesper Roos, Samantha Mellen, Daniel Turnock and Alison Jones
Diagnostics Kits - Information for the Public
Alpha Laboratories is a supplier of diagnostic kits for use by professional medical personnel within a clinical laboratory or doctors surgery. They are sold only to professionals for use in medical diagnostic or screening programmes. They are not available to the general public for home testing.
Whilst some of the sample collection may be carried out at home, the performance of the tests and analysis of results must be done by professionals in a clinical environment. This is to ensure correct procedures are followed, avoid potential interference from procedural or clinical conditions and certify accurate interpretation of results. As such these tests are not validated for use by non professionals.
For any concerns you may have please consult with your GP who should be able to advise you.
Alternatively the following websites may provide additional help:
NHS Bowel Cancer Screening: http://www.cancerscreening.nhs.uk/bowel/
Bowel Cancer UK: http://www.bowelcanceruk.org.uk/understanding-bowel-cancer/screening/
Lab Tests Online: http://www.labtestsonline.org.uk/
The IBS Network: http://www.theibsnetwork.org/
Crohn's and Colitis UK: http://www.nacc.org.uk/
Crohn's Support: http://www.crohnsupport.com/